Today's Trend
Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares are trading higher after research notes from Ascendiant Capital Markets (analyst E. Woo) updated 2026–2027 EPS forecasts while reiterating a Buy rating and a $9.75 price target. The firm slightly improved its Q1 and full‑year 2026 outlook but trimmed several quarterly EPS calls, leaving investors to focus on the maintained constructive rating and target.
- Ascendiant raised its Q1 2026 EPS estimate to ($0.22) from ($0.24), a modest beat to the downside that suggests a slightly less negative near‑term cash burn view. Ascendiant raises Q1 2026 estimate
- The firm also nudged FY2026 EPS to ($0.96) from ($0.97), a marginal improvement that supports the continuation of its Buy rating and $9.75 target — a factor likely supporting buying interest despite negative EPS. Ascendiant adjusts FY2026 estimate
- Ascendiant published a full slate of 2027 quarterly and FY estimates (each quarter ~($0.24); FY2027 ~$0.97 negative) — useful for modeling but not a material directional surprise versus its 2026 view. Ascendiant issues 2027 estimates
- Ascendiant trimmed Q2, Q3 and Q4 2026 EPS estimates from ($0.24) to ($0.25) for each quarter, signaling slightly wider near‑term losses than previously expected — a potential headwind for sentiment if results track lower. Ascendiant trims several 2026 quarterly estimates
- Ascendiant kept a Buy rating and a relatively high $9.75 price objective, which supports upside narratives for long‑term investors but contrasts with the company’s negative EPS profile; note the report repeats a widely divergent “consensus” EPS figure (listed as ($78.08)), which appears anomalous and should be treated cautiously. Analyst rating and target reiterated
Investor takeaway: the stock’s uptick reflects relief that a covering analyst left a Buy rating and $9.75 target intact and made only modest mix‑ed changes to quarterly forecasts (some slight improvements offset by small trims). Monitor upcoming operational updates and actual quarterly results to see whether the minor EPS downgrades materialize.